Drug Profile
Apomorphine sublingual - Amarin Corporation
Alternative Names: Apomorphine oralLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator
- Developer Amarin Corporation
- Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Quinolines; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 19 Feb 2009 No development reported - Phase-I for Parkinson's disease in United Kingdom (Sublingual)
- 25 Sep 2008 Apomorphine sublingual is available for licensing (http://www.amarincorp.com)
- 13 Aug 2007 Amarin Corporation completes a phase I trial in healthy volunteers